GET DAILY SIGNALSSummit Therapeutics (SMMT) Q3 2026 Earnings Preview Ahead of Pivotal FDA Decision
Key Takeaways
- Summit Therapeutics is expected to report third quarter 2026 results around November 11, 2026, after the market close, covering the period ended September 30, 2026.
- Consensus estimates point to a generally accepted accounting principles (GAAP) loss per share of roughly $0.28 to $0.29, with revenue expected to remain minimal as the company is still pre-commercial.
- The report lands just days before the U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) goal action date of November 14, 2026, for ivonescimab in EGFR-mutated non-small cell lung cancer (NSCLC).
- Investors will focus on the cash position, research and development (R&D) spending trends, and updates across the company's three ongoing Phase III clinical trials.
Why This Earnings Report Stands Out
Summit Therapeutics Inc. (SMMT) is a clinical-stage biopharmaceutical company that has drawn significant attention in oncology due to ivonescimab (SMT112), a bispecific antibody targeting both PD-1 and VEGF. With essentially no product revenue at present, the quarterly results reflect development spending rather than sales activity. This makes the upcoming report notable primarily because it arrives just days before a potential first FDA approval decision. I am watching closely to see how the financial update signals readiness for a commercial launch and the broader late-stage trial program.
What Analysts Expect from the Numbers
Given the pre-revenue status, the focus will be on the net loss. Wall Street consensus anticipates a GAAP loss per share in the range of roughly $0.28 to $0.29 for the third quarter of 2026, with revenue forecasts remaining negligible, typically below $0.1 million. In the second quarter of 2026, Summit Therapeutics Inc. (SMMT) posted a wider-than-expected GAAP loss, with research and development costs rising about 24% quarter over quarter to roughly $151.8 million in operating expenses amid three active Phase III trials and increased stock-based compensation. The company closed that quarter with approximately $690.7 million in cash, cash equivalents, and short-term investments, and it has since established a new $380 million at-the-market equity facility. For the third quarter, attention will turn to whether expense growth persisted and what the cash balance looks like heading into a possible launch period. I also checked this using Tickeron’s AI Screener to compare spending trends with peers in the sector.
Market Sentiment and Potential Reaction
Investor focus ahead of the release centers more on the regulatory timeline than the financial details themselves. Summit Therapeutics Inc. (SMMT) shares have moved within a wide range over the past year, and the stock maintains elevated short interest. Following the second-quarter report and its wider loss, shares fell in after-hours trading, highlighting sensitivity to spending patterns and cash burn. Key items to monitor include the pace of expense growth, any effects from the ATM facility, and the implications of the upcoming FDA decision. Because the PDUFA date comes so soon after, the earnings call may offer early clues on commercialization readiness.
Key Items to Watch Going Forward
The primary near-term catalyst remains the FDA’s PDUFA goal action date of November 14, 2026, for ivonescimab in EGFR-mutated NSCLC. An approval would shift Summit Therapeutics Inc. (SMMT) toward commercial operations and redirect attention to launch execution. Beyond that, investors should track the Phase III program, including top-line progression-free survival data from the HARMONi-3 squamous cohort expected in the second half of 2026 and an interim overall survival analysis anticipated in the first half of 2027. Additional collaboration data is slated around mid-2027. On the financial front, the cash runway and management of rising R&D plus selling, general, and administrative costs will matter ahead of a potential launch. The ATM facility adds flexibility yet raises dilution considerations. From what I see, this analysis does not constitute a price forecast or investment recommendation.
Exploring AI Tools in My Research Process
In my own analysis of event-driven names like this, I frequently turn to Tickeron’s AI Trading Bots to test how automated strategies might respond around regulatory and earnings windows. The platform lets users examine virtual agents across different market conditions, offering a practical way to layer quantitative perspectives onto fundamental research without replacing core due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SMMT in downward trend: 10-day moving average crossed below 50-day moving average on October 23, 2026
The 10-day moving average for SMMT crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 58 cases where SMMT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SMMT as a result. In 88 of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for SMMT turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 41 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
SMMT moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SMMT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for SMMT entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
Following a +5.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where SMMT advanced for three days, in 243 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. SMMT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 73 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SMMT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.741) is normal, around the industry mean (3.104). P/E Ratio (-13.333) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.310) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel medicines
Industry Biotechnology
Advertisement